Squarepoint Ops LLC Acquires 47,221 Shares of Twist Bioscience Corporation $TWST

Squarepoint Ops LLC raised its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 192.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,708 shares of the company’s stock after acquiring an additional 47,221 shares during the quarter. Squarepoint Ops LLC’s holdings in Twist Bioscience were worth $2,638,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. raised its position in shares of Twist Bioscience by 1,121.3% in the 1st quarter. Russell Investments Group Ltd. now owns 108,834 shares of the company’s stock worth $4,273,000 after acquiring an additional 99,923 shares in the last quarter. American Century Companies Inc. grew its stake in Twist Bioscience by 0.9% in the first quarter. American Century Companies Inc. now owns 763,406 shares of the company’s stock valued at $29,971,000 after purchasing an additional 7,054 shares during the last quarter. Hsbc Holdings PLC bought a new position in Twist Bioscience in the first quarter worth about $228,000. Virtus Advisers LLC bought a new position in Twist Bioscience in the first quarter worth about $836,000. Finally, Rafferty Asset Management LLC lifted its position in shares of Twist Bioscience by 6.4% during the first quarter. Rafferty Asset Management LLC now owns 99,284 shares of the company’s stock valued at $3,898,000 after buying an additional 5,965 shares during the last quarter.

Twist Bioscience Trading Up 3.2%

NASDAQ TWST opened at $32.13 on Thursday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $55.33. The company has a fifty day simple moving average of $30.90 and a two-hundred day simple moving average of $31.14. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.96 billion, a P/E ratio of -24.53 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The firm had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million. On average, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 9,724 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $313,015.56. Following the completion of the transaction, the senior vice president directly owned 114,678 shares of the company’s stock, valued at approximately $3,691,484.82. This trade represents a 7.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 31,379 shares of Twist Bioscience stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $986,555.76. Following the sale, the chief executive officer owned 738,809 shares of the company’s stock, valued at approximately $23,228,154.96. The trade was a 4.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 119,110 shares of company stock valued at $3,783,237. 3.01% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TWST. Barclays lifted their price objective on shares of Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday. Evercore ISI decreased their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Finally, Stephens started coverage on Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.88.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.